Leveraging a Deep Learning Model and Computational Screening for the Discovery of ABCG2 Inhibitors against Drug-Resistant Breast Cancer
Journal of Chemical Information and Modeling · 2026
DOI: 10.1021/acs.jcim.6c00582 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Chemical Information and Modeling, 2026. Verfasst von Haonan Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: MOE Key Laboratory of Bio-Intelligent Manufacturing, School of Bioengineering, Dalian University of Technology, Dalian, Liaoning116024, China. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily G, Member 2, Deep Learning, Drug Resistance, Neoplasm, Breast Neoplasms. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Shanghai University of Medicine and Health Sciences, Key Research and Development Program of Liaoning Province.
Abstract (Originalsprache)
Multidrug resistance (MDR) mediated by ATP-binding cassette transporter G2 (ABCG2) remains a major clinical challenge in breast cancer chemotherapy, primarily due to its role in reducing intracellular adriamycin (ADR) concentrations. To address this challenge, we developed an integrated computational strategy for the rapid identification of potent ABCG2 inhibitors capable of reversing ADR resistance. We first established the Prediction of Protein–Ligand’s pKd (PPLK), a specialized deep learning model that employs multimodal sequence-ligand representations and feedforward neural networks to accelerate the discovery of ABCG2 inhibitors. Next, computational virtual screening of a compound library (∼1.58 million) was conducted, coupled with molecular dynamics simulations, focusing on the key binding residues THR542, PHE439, ASN436, and SER440. Among the top-ranked candidates, reserpine was validated as a potent ABCG2 inhibitor, achieving 1.90-fold sensitization in ADR-resistant cells, thereby confirming the predictive accuracy of the PPLK model. Notably, we identified a small-molecule compound, F0161-0219, as a promising ABCG2 inhibitor, which led to a 1.94-fold sensitization enhancement in ADR-resistant cells. Direct target engagement of F0161-0219 with ABCG2 was confirmed by biolayer interferometry, DARTS, and CETSA assays. Collectively, our research underscores the potential of leveraging deep learning models and computational screening for the discovery of ABCG2 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- MOE Key Laboratory of Bio-Intelligent Manufacturing, School of Bioengineering, Dalian University of Technology, Dalian, Liaoning116024, China.
- Department of Biomedical Engineering, College of Basic Medical Sciences, Dalian Medical University, Dalian, Liaoning116044, China.
ORCID-Profile: Haonan Li, Yongliang Yang
Förderung
- Shanghai University of Medicine and Health Sciences
- Key Research and Development Program of Liaoning Province
Zitieren
APA
Li, H., Wang, Z., Wang, J., & Yang, Y. (2026). Leveraging a Deep Learning Model and Computational Screening for the Discovery of ABCG2 Inhibitors against Drug-Resistant Breast Cancer. Journal of Chemical Information and Modeling. https://doi.org/10.1021/acs.jcim.6c00582
Vancouver
Li H, Wang Z, Wang J, Yang Y. Leveraging a Deep Learning Model and Computational Screening for the Discovery of ABCG2 Inhibitors against Drug-Resistant Breast Cancer. Journal of Chemical Information and Modeling. 2026. doi:10.1021/acs.jcim.6c00582
BibTeX
@article{Li2026,
author = {Li, Haonan and Wang, Zichu and Wang, Jia and Yang, Yongliang},
title = {Leveraging a Deep Learning Model and Computational Screening for the Discovery of ABCG2 Inhibitors against Drug-Resistant Breast Cancer},
journal = {Journal of Chemical Information and Modeling},
year = {2026},
doi = {10.1021/acs.jcim.6c00582}
}
EUVIMED